Thomas C. Harding

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy et al. · Nature Communications · 2016 · 659 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 627 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza et al. · Cancer Discovery · 2018 · 432 citations

Medicine, Molecular Genetics, Oncology +17